Citius Pharmaceuticals (NASDAQ:CTXR) Releases Earnings Results, Misses Expectations By $1.34 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) issued its quarterly earnings data on Friday. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34), FiscalAI reports.

Citius Pharmaceuticals Stock Performance

NASDAQ CTXR traded down $0.02 during trading on Friday, hitting $0.70. The stock had a trading volume of 516,793 shares, compared to its average volume of 1,069,212. The firm has a 50 day moving average price of $0.79 and a 200 day moving average price of $0.92. Citius Pharmaceuticals has a twelve month low of $0.57 and a twelve month high of $2.48.

Hedge Funds Weigh In On Citius Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Citius Pharmaceuticals in the 2nd quarter valued at about $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the 2nd quarter valued at about $40,000. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals in the 4th quarter valued at about $46,000. Finally, Heights Capital Management Inc. acquired a new position in Citius Pharmaceuticals in the 4th quarter valued at about $622,000. 16.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CTXR has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. D. Boral Capital reissued a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Citius Pharmaceuticals has an average rating of “Hold” and an average price target of $6.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.